re tend to do well because the decrease in income help consumers allocate more of their assets into these inelastic companies. Such distribution aids in future earnings and revenue growth, and CYTO is no exception to such a trend.

With excellent fundamentals, and opt

Coming off its 52 week high and its recently reported earnings (August 7, 2006), Cytrogen Corporation may be one of the best buys you can find out there. The company recently posted excellent fundamentals with a 0.32 EPS when the market was expecting -0.30, and increased both its revenue and profit relative to one year ago.

For the most part, a lot of the extra income had come from Cytrogen's joint venture with PSMA Corporations, but such an activity does not mean that CYTO is not a perfect buying opportunity. While a few investors may argue that the stock was recently near two dollars which exceeded its previous 52 week low, CYTO is continuously growing and still presents itself as a chance for a profitable mid to long term investment.

As a biopharmaceutical company, such a sector usually does well during periods of slow economic growth. As interest rates are at near its maximum, economic growth will become a bit of concern but should ironically help CYTO's price. Typically, during slow growth inelastic goods and services produced by companies such as in healthcare tend to do well because the decrease in income help consumers allocate more of their assets into these inelastic companies. Such distribution aids in future earnings and revenue growth, and CYTO is no exception to such a trend.

With excellent fundamentals, and opti

oth its revenue and profit relative to one year ago.

For the most part, a lot of the extra income had come from Cytrogen's joint venture with PSMA Corporations, but such an activity does not mean that CYTO is not a perfect buying opportunity. While a few investors may argue that the stock was recently near two dollars which exceeded its previous 52 week low, CYTO is continuously growing and still presents itself as a chance for a profitable mid to long term investment.

As a biopharmaceutical company, such a sector usually does well during periods of slow economic growth. As interest rates are at near its maximum, economic growth will become a bit of concern but should ironically help CYTO's price. Typically, during slow growth inelastic goods and services produced by companies such as in healthcare tend to do well because the decrease in income help consumers allocate more of their assets into these inelastic companies. Such distribution aids in future earnings and revenue growth, and CYTO is no exception to such a trend.

With excellent fundamentals, and opt

y argue that the stock was recently near two dollars which exceeded its previous 52 week low, CYTO is continuously growing and still presents itself as a chance for a profitable mid to long term investment.

As a biopharmaceutical company, such a sector usually does well during periods of slow economic growth. As interest rates are at near its maximum, economic growth will become a bit of concern but should ironically help CYTO's price. Typically, during slow growth inelastic goods and services produced by companies such as in healthcare tend to do well because the decrease in income help consumers allocate more of their assets into these inelastic companies. Such distribution aids in future earnings and revenue growth, and CYTO is no exception to such a trend.

With excellent fundamentals, and opt

ell during periods of slow economic growth. As interest rates are at near its maximum, economic growth will become a bit of concern but should ironically help CYTO's price. Typically, during slow growth inelastic goods and services produced by companies such as in healthcare tend to do well because the decrease in income help consumers allocate more of their assets into these inelastic companies. Such distribution aids in future earnings and revenue growth, and CYTO is no exception to such a trend.

With excellent fundamentals, and opt

re tend to do well because the decrease in income help consumers allocate more of their assets into these inelastic companies. Such distribution aids in future earnings and revenue growth, and CYTO is no exception to such a trend.

With excellent fundamentals, and optimistic outlook, and price just coming out of its 52 week low, I would look for CYTO to be a real bargain around the 2.30-2.50 mark. Having a 52 week high of near 5.30, a 17.00 one year target, and positive, but relatively not to high P/E ratio this quarter, I would absolutely recommend Cytrogen as a strong buy.